Genedata and the Drug Discovery Center at the University of Cincinnati Announce High Throughput Screening Collaboration

Basel, Switzerland, November 5, 2008

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced a High Throughput Screening (HTS) collaboration with the Drug Discovery Center at the Genome Research Institute (GRI), University of Cincinnati. Genedata Screener®, an open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS), will be completely integrated into the center’s HTS workflows.

The Drug Discovery Center is working on molecular probes for application in the pharmaceutical and biotech industries and needed a software solution to manage and analyze their small molecule screening campaigns. The Screener platform combines enterprise-wide assay data management with high-performance processing workflows and flexible analysis tools to rapidly analyze, integrate and manage all assay data, independent of instrumentation, technology, volume or location.

“The Screener system from Genedata matched our screening and analysis workflows and is easy to use. Users can start working with Screener on the fly and need very little additional IT support,” explained Dr. Sandra Nelson, director of High Throughput Screening and research associate professor at the University of Cincinnati. “Another key feature for us is the automated quality control which has reduced analysis and review time from days to mere hours per screen.“

Dr. Othmar Pfannes, CEO of Genedata, stated, “Genedata is excited to be working with the Drug Discovery Center to help forward their innovative research in screening of small molecules and cell-based assays. We are pleased to continue to provide tailored solutions for a broad range of applications including academic research projects.”

About The Drug Discovery Center
The Drug Discovery Center at the GRI is dedicated to the discovery and early development of novel and commercially viable therapeutic applications. The Drug Discovery Center offers academic and industry scientists access to computational biology, high-throughput screening (HTS), medicinal chemistry and a 250,000 pharma-quality small molecule compound library. The Drug Discovery Center is managed by experienced pharmaceutical industry trained managers and staff. Strategically placed at the intersection of established academic and industrial entities, the Drug Discovery Center is designed to fulfill both scientific and commercial objectives.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

Contact
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.